Gefitinib in front line treatment of patients with NSCLC in the Czech republic: Analysis of 113 patients

• Authors: SKŘIČKOVÁ Jana; BORTLÍČEK Zbyněk; HEJDUK Karel; PEŠEK Milos; KOLEK Vitezslav; KOUBKOVÁ Lucie; TOMÍŠKOVÁ Marcela; ROUBEC Jaromir; HAVEL Libor; SALAJKA Frantisek; GRYGARKOVA Ivona; HRNCIARIK Michal; SATANKOVA Monika; POVOLNA Zdenka; CERNOVSKA Marketa; MAREL Miroslav; VASAKOVA Martina
• Year of publication: 2014
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Gefitinib is the active and selective EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor). This study evaluates treatment outcomes in 113 NSCLC patients with activating EGFR mutation.